Rasmussen H - Search Results

1

Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).

Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU. Rasmussen H, et al. Hum Gene Ther. 2001 Nov 1;12(16):2029-32. Hum Gene Ther. 2001. PMID: 11727737 Clinical Trial.

2

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Harvey BG, et al. Hum Gene Ther. 2002 Jan 1;13(1):15-63. doi: 10.1089/10430340152712638. Hum Gene Ther. 2002. PMID: 11779412 Clinical Trial.

3

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.

Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Crystal RG, et al. Hum Gene Ther. 2002 Jan 1;13(1):65-100. doi: 10.1089/10430340152712647. Hum Gene Ther. 2002. PMID: 11779413 Clinical Trial.

4

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.

Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. Senzer N, et al. Among authors: rasmussen c, rasmussen h. J Clin Oncol. 2004 Feb 15;22(4):592-601. doi: 10.1200/JCO.2004.01.227. Epub 2004 Jan 15. J Clin Oncol. 2004. PMID: 14726502 Clinical Trial.

5

Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.

Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS. Stewart DJ, et al. Among authors: rasmussen c, rasmussen hs. Gene Ther. 2006 Nov;13(21):1503-11. doi: 10.1038/sj.gt.3302802. Epub 2006 Jun 22. Gene Ther. 2006. PMID: 16791287 Clinical Trial.

6

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.

Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, Weichselbaum R. Rasmussen H, et al. Among authors: rasmussen c. Cancer Gene Ther. 2002 Nov;9(11):951-7. doi: 10.1038/sj.cgt.7700518. Cancer Gene Ther. 2002. PMID: 12386834

7

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.

Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. Mundt AJ, et al. Among authors: rasmussen cs, rasmussen hs. Clin Cancer Res. 2004 Sep 1;10(17):5747-53. doi: 10.1158/1078-0432.CCR-04-0296. Clin Cancer Res. 2004. PMID: 15355902 Clinical Trial.

8

Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication.

Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R, Rasmussen H, Crystal R. Rajagopalan S, et al. Among authors: rasmussen h. Am J Cardiol. 2002 Sep 1;90(5):512-6. doi: 10.1016/s0002-9149(02)02524-9. Am J Cardiol. 2002. PMID: 12208412 Clinical Trial.

9

Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.

Mohler ER 3rd, Rajagopalan S, Olin JW, Trachtenberg JD, Rasmussen H, Pak R, Crystal RG. Mohler ER 3rd, et al. Among authors: rasmussen h. Vasc Med. 2003;8(1):9-13. doi: 10.1191/1358863x03vm460oa. Vasc Med. 2003. PMID: 12866606 Clinical Trial.

10

VEGF gene therapy for coronary artery disease and peripheral vascular disease.

Rasmussen HS, Rasmussen CS, Macko J. Rasmussen HS, et al. Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. doi: 10.1016/s1522-1865(02)00158-0. Cardiovasc Radiat Med. 2002. PMID: 12699842 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,449 results

Search Page